Potential Visualized in AstraZeneca (AZN); Intrigue Growing Around Amaya (AYA)

http://galaxystocks.com/wp-content/uploads/2016/11/AstraZeneca_AZN.jpg

Analysts at Liberum upgraded AstraZeneca plc (NYSE:AZN) to a Buy from a Hold rating, pushing its stock into positive territory on Friday to finally close at $27.10, up $0.73 (or +2.77%) with a total volume of 9.57M shares traded.

The global, science-led biopharmaceutical company resumed last week enrolment of patients with head and neck cancer after the FDA lifted the partial clinical hold on new patient enrolment for clinical trials testing the potential of its investigational human monoclonal antibody durvalumab

AstraZeneca, which engages in the discovery, development, and commercialization of prescription medicines for the treatment of respiratory, inflammation, autoimmune, cardiovascular, metabolic, oncology, infection, neuroscience, and gastrointestinal diseases, has 1.26B Shares Outstanding, Market Capitalization (intraday) of $69.61B and AZN stock 52-week range is between $25.88 and $35.04 per share

*

http://galaxystocks.com/wp-content/uploads/2016/05/Amaya_AYA.jpg

Amaya Inc. (Nasdaq:AYA) shares surged 7.53% (or +$1.05) to $15.00 on Friday’s half-day trading session after the company’s ex-CEO David Baazov said in a SEC filing ( SC 13D/A ) that a group led by him secured new financing commitments – CAD$3.45 billion – from Head and Shoulders Global Investment Fund SPC and Goldenway Capital SPC for a buyout plan for the PokerStars owner.

The online gaming company recently delivered third quarter 2016 revenues of $270.85 million and adjusted net income of $84.98 million, or $0.42 per diluted share for the period

Amaya, which provides technology-based products and services to the global gaming and interactive entertainment industries, has 144.96M Shares Outstanding, Market Capitalization (intraday) of $2.17B and AYA stock one-year range is from $9.67 to $17.57 per share.

**

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/